CORRESP 1 filename1.htm CORRESP

January 10, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:

Coya Therapeutics, Inc. (the “Company”)

Registration Statement on Form S-3 (File No. 333-276374)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 5:00 p.m., Eastern Time, on January 12, 2024, or as soon as practicable thereafter.

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.

 

Very truly yours,
COYA THERAPEUTICS, INC.
By:   /s/ Howard Berman
Name:   Howard Berman
Title:  

Chief Executive Officer

(Principal Executive Officer)